CN105497053A - 可利霉素在抗结核分枝杆菌感染中的应用 - Google Patents
可利霉素在抗结核分枝杆菌感染中的应用 Download PDFInfo
- Publication number
- CN105497053A CN105497053A CN201511030787.7A CN201511030787A CN105497053A CN 105497053 A CN105497053 A CN 105497053A CN 201511030787 A CN201511030787 A CN 201511030787A CN 105497053 A CN105497053 A CN 105497053A
- Authority
- CN
- China
- Prior art keywords
- mycobacterium tuberculosis
- clinical
- rokitamycin
- kelimycin
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000008827 tuberculosis Diseases 0.000 title claims abstract description 20
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims abstract description 45
- 239000003814 drug Substances 0.000 claims abstract description 23
- VYWWNRMSAPEJLS-MDWYKHENSA-N Rokitamycin Chemical compound C1[C@](OC(=O)CC)(C)[C@@H](OC(=O)CCC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](O)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C VYWWNRMSAPEJLS-MDWYKHENSA-N 0.000 claims description 38
- 229960001170 rokitamycin Drugs 0.000 claims description 38
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 24
- 229960003350 isoniazid Drugs 0.000 abstract description 17
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 abstract description 17
- 229930189077 Rifamycin Natural products 0.000 abstract description 16
- 229960003292 rifamycin Drugs 0.000 abstract description 16
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 abstract description 16
- 241000894006 Bacteria Species 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 206010059866 Drug resistance Diseases 0.000 abstract description 7
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 230000001355 anti-mycobacterial effect Effects 0.000 abstract 1
- 229940124976 antitubercular drug Drugs 0.000 abstract 1
- 239000000814 tuberculostatic agent Substances 0.000 abstract 1
- 230000002365 anti-tubercular Effects 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 4
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 3
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 3
- 108010065839 Capreomycin Proteins 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 206010034133 Pathogen resistance Diseases 0.000 description 3
- 239000004187 Spiramycin Substances 0.000 description 3
- 229960004821 amikacin Drugs 0.000 description 3
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 3
- 229960004099 azithromycin Drugs 0.000 description 3
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229960004602 capreomycin Drugs 0.000 description 3
- 229960002626 clarithromycin Drugs 0.000 description 3
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000003120 macrolide antibiotic agent Substances 0.000 description 3
- 229960001699 ofloxacin Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 3
- 229960001294 spiramycin Drugs 0.000 description 3
- 229930191512 spiramycin Natural products 0.000 description 3
- 235000019372 spiramycin Nutrition 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 2
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 229960000285 ethambutol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 229960005206 pyrazinamide Drugs 0.000 description 2
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 229960005224 roxithromycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 206010060976 Bacillus infection Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 241000692870 Inachis io Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- DMUAPQTXSSNEDD-QALJCMCCSA-N Midecamycin Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960002001 ethionamide Drugs 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- -1 isovaleryl spiramycin Chemical compound 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 229960002757 midecamycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- BRFSQIYPQCRVET-FHNDMYTFSA-M sodium;(2r)-2-acetamido-3-sulfanylpropanoic acid;hydroxide Chemical compound [OH-].[Na+].CC(=O)N[C@@H](CS)C(O)=O BRFSQIYPQCRVET-FHNDMYTFSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (3)
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201511030787.7A CN105497053B (zh) | 2015-12-31 | 2015-12-31 | 可利霉素在抗结核分枝杆菌感染中的应用 |
PE2018001212A PE20190210A1 (es) | 2015-12-31 | 2016-12-05 | Aplicaciones de carrimicina en la infeccion por micobacterium tuberculosis resistente |
ES16880885T ES2785644T3 (es) | 2015-12-31 | 2016-12-05 | Carrimicina para el tratamiento de infecciones por Mycobacterium tuberculosis |
DK16880885.5T DK3384915T3 (en) | 2015-12-31 | 2016-12-05 | Carrimycin til behandling af mycobacterium tuberculosis-infektioner |
PCT/CN2016/108502 WO2017114095A1 (zh) | 2015-12-31 | 2016-12-05 | 可利霉素在抗结核分枝杆菌感染中的应用 |
PL16880885T PL3384915T3 (pl) | 2015-12-31 | 2016-12-05 | Karymycyna do leczenia zakażeń prątkiem gruźlicy |
RU2018125622A RU2733382C2 (ru) | 2015-12-31 | 2016-12-05 | Способ применения карримицина против резистентности инфекции, спровоцированной микобактерией туберкулеза |
JP2018553283A JP6770584B2 (ja) | 2015-12-31 | 2016-12-05 | 抗結核感染におけるカリマイシン(Kelimycin)の応用 |
AU2016382584A AU2016382584B2 (en) | 2015-12-31 | 2016-12-05 | Applications of kelimycin in mycobacterium tuberculosis infection resistance |
KR1020187021578A KR20180098624A (ko) | 2015-12-31 | 2016-12-05 | 결핵균 마이코박테리움 터버큘로시스(Mycobacterium tuberculosis) 감염 저항성에서의 켈리마이신의 응용 |
BR112018013327-2A BR112018013327A2 (zh) | 2015-12-31 | 2016-12-05 | Application of Rimycin in Anti - tuberculosis Mycobacterium Infection |
US16/067,327 US11000708B2 (en) | 2015-12-31 | 2016-12-05 | Use of carrimycin in Mycobacterium tuberculosis infection resistance |
EP16880885.5A EP3384915B1 (en) | 2015-12-31 | 2016-12-05 | Carrimycin for the treatment of mycobacterium tuberculosis infections |
MYPI2018001121A MY191800A (en) | 2015-12-31 | 2016-12-05 | Use of carrimycin in mycobacterium tuberculosis infection resistance |
CA3010020A CA3010020A1 (en) | 2015-12-31 | 2016-12-05 | Use of carrimycin in mycobacterium tuberculosis infection resistance |
UAA201808048A UA121159C2 (uk) | 2015-12-31 | 2016-12-05 | Застосування кариміцину при стійкості інфекції мycobacterium tuberculosis |
PH12018501394A PH12018501394A1 (en) | 2015-12-31 | 2018-06-28 | Use of carrimycin in mycobacterium tuberculosis infection resistance |
ZA2018/04398A ZA201804398B (en) | 2015-12-31 | 2018-06-29 | Use of carrimycin in mycobacterium tuberculosis infection resistance |
CL2018001804A CL2018001804A1 (es) | 2015-12-31 | 2018-06-29 | Uso de la carrimicina en la infección por micobacterium tuberculosis resistente |
CONC2018/0007133A CO2018007133A2 (es) | 2015-12-31 | 2018-07-09 | Uso de la carrimicina en la infección por micobacterium tuberculosis resistente |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201511030787.7A CN105497053B (zh) | 2015-12-31 | 2015-12-31 | 可利霉素在抗结核分枝杆菌感染中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105497053A true CN105497053A (zh) | 2016-04-20 |
CN105497053B CN105497053B (zh) | 2018-02-13 |
Family
ID=55705614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201511030787.7A Active CN105497053B (zh) | 2015-12-31 | 2015-12-31 | 可利霉素在抗结核分枝杆菌感染中的应用 |
Country Status (20)
Country | Link |
---|---|
US (1) | US11000708B2 (zh) |
EP (1) | EP3384915B1 (zh) |
JP (1) | JP6770584B2 (zh) |
KR (1) | KR20180098624A (zh) |
CN (1) | CN105497053B (zh) |
AU (1) | AU2016382584B2 (zh) |
BR (1) | BR112018013327A2 (zh) |
CA (1) | CA3010020A1 (zh) |
CL (1) | CL2018001804A1 (zh) |
CO (1) | CO2018007133A2 (zh) |
DK (1) | DK3384915T3 (zh) |
ES (1) | ES2785644T3 (zh) |
MY (1) | MY191800A (zh) |
PE (1) | PE20190210A1 (zh) |
PH (1) | PH12018501394A1 (zh) |
PL (1) | PL3384915T3 (zh) |
RU (1) | RU2733382C2 (zh) |
UA (1) | UA121159C2 (zh) |
WO (1) | WO2017114095A1 (zh) |
ZA (1) | ZA201804398B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017114095A1 (zh) * | 2015-12-31 | 2017-07-06 | 沈阳同联集团有限公司 | 可利霉素在抗结核分枝杆菌感染中的应用 |
WO2018184587A1 (zh) * | 2017-04-06 | 2018-10-11 | 沈阳福洋医药科技有限公司 | 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用 |
CN110384710A (zh) * | 2018-04-17 | 2019-10-29 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗疼痛的药物、组合产品及其应用 |
CN110384802A (zh) * | 2018-04-17 | 2019-10-29 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗发热的药物、组合产品及其应用 |
WO2021219112A1 (zh) * | 2020-04-30 | 2021-11-04 | 沈阳福洋医药科技有限公司 | 异戊酰螺旋霉素类化合物或其组合物在制备治疗脓毒症疾病药物中的应用 |
WO2021219113A1 (zh) * | 2020-04-30 | 2021-11-04 | 沈阳福洋医药科技有限公司 | 异戊酰螺旋霉素类化合物或其组合物在制备治疗免疫失调的药物中的应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022119899A1 (en) * | 2020-12-02 | 2022-06-09 | Shionogi & Co., Ltd. | A medicament for treating mycobacterial infection characterized by combining a cytochrome bc1 inhibitor with clarithromycin or azithromycin |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1554355A (zh) * | 2003-12-23 | 2004-12-15 | 沈阳同联集团有限公司 | 必特螺旋霉素及其在抗感染性疾病中的应用 |
WO2007065637A1 (de) * | 2005-12-06 | 2007-06-14 | Andreas Kern | Oral einzunehmende antibiotika zur behandlung von hämorrhoidenleiden |
WO2008122038A1 (en) * | 2007-04-02 | 2008-10-09 | President And Fellows Of Harvard College | Regulating autophagy |
CN103142520A (zh) * | 2013-03-15 | 2013-06-12 | 沈阳同联集团有限公司 | 一种可利霉素片及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2126108B1 (zh) * | 1971-02-25 | 1974-08-02 | Rhone Poulenc Sa | |
US7098219B2 (en) * | 2000-08-01 | 2006-08-29 | Wockhart Limited | Inhibitors of cellular efflux pumps of microbes |
US20080161249A1 (en) * | 2004-11-17 | 2008-07-03 | Smithkline Beecham Corporation | Use of Novel Antibacterial Compounds |
PL3210990T3 (pl) * | 2010-05-25 | 2020-10-05 | Shenyang Fuyang Pharmaceutical Technology Co., Ltd. | Lewoizowalerylospiramycyna III i jej preparaty, sposoby wytwarzania i zastosowania |
CA2800019C (en) * | 2010-05-25 | 2015-05-26 | Shenyang Tonglian Group Co., Ltd. | Levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof |
JP6116206B2 (ja) * | 2012-11-26 | 2017-04-19 | クリニプロ株式会社 | 吸入用パウダーの製造方法 |
CN105497053B (zh) | 2015-12-31 | 2018-02-13 | 沈阳福洋医药科技有限公司 | 可利霉素在抗结核分枝杆菌感染中的应用 |
-
2015
- 2015-12-31 CN CN201511030787.7A patent/CN105497053B/zh active Active
-
2016
- 2016-12-05 PE PE2018001212A patent/PE20190210A1/es unknown
- 2016-12-05 BR BR112018013327-2A patent/BR112018013327A2/zh active Search and Examination
- 2016-12-05 WO PCT/CN2016/108502 patent/WO2017114095A1/zh active Application Filing
- 2016-12-05 US US16/067,327 patent/US11000708B2/en active Active
- 2016-12-05 RU RU2018125622A patent/RU2733382C2/ru active
- 2016-12-05 MY MYPI2018001121A patent/MY191800A/en unknown
- 2016-12-05 CA CA3010020A patent/CA3010020A1/en active Pending
- 2016-12-05 KR KR1020187021578A patent/KR20180098624A/ko active Search and Examination
- 2016-12-05 EP EP16880885.5A patent/EP3384915B1/en active Active
- 2016-12-05 UA UAA201808048A patent/UA121159C2/uk unknown
- 2016-12-05 PL PL16880885T patent/PL3384915T3/pl unknown
- 2016-12-05 DK DK16880885.5T patent/DK3384915T3/da active
- 2016-12-05 ES ES16880885T patent/ES2785644T3/es active Active
- 2016-12-05 JP JP2018553283A patent/JP6770584B2/ja active Active
- 2016-12-05 AU AU2016382584A patent/AU2016382584B2/en active Active
-
2018
- 2018-06-28 PH PH12018501394A patent/PH12018501394A1/en unknown
- 2018-06-29 CL CL2018001804A patent/CL2018001804A1/es unknown
- 2018-06-29 ZA ZA2018/04398A patent/ZA201804398B/en unknown
- 2018-07-09 CO CONC2018/0007133A patent/CO2018007133A2/es unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1554355A (zh) * | 2003-12-23 | 2004-12-15 | 沈阳同联集团有限公司 | 必特螺旋霉素及其在抗感染性疾病中的应用 |
WO2007065637A1 (de) * | 2005-12-06 | 2007-06-14 | Andreas Kern | Oral einzunehmende antibiotika zur behandlung von hämorrhoidenleiden |
WO2008122038A1 (en) * | 2007-04-02 | 2008-10-09 | President And Fellows Of Harvard College | Regulating autophagy |
CN103142520A (zh) * | 2013-03-15 | 2013-06-12 | 沈阳同联集团有限公司 | 一种可利霉素片及其制备方法 |
Non-Patent Citations (3)
Title |
---|
FALZARI KANAKESHWARI等: "In Vitro and In Vivo Activities of Macrolide Derivatives against Mycobacterium tuberculosis", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 * |
JEFFREY L.H ET AL: ""The Structures of Four Macrolide Antibiotics Bound to the Large Ribosomal Subunit"", 《MOLECULAR CELL》 * |
戴剑漉等: "新一代必特螺旋霉素基因工程菌的微波诱变", 《中国抗生素杂志》 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017114095A1 (zh) * | 2015-12-31 | 2017-07-06 | 沈阳同联集团有限公司 | 可利霉素在抗结核分枝杆菌感染中的应用 |
US11000708B2 (en) | 2015-12-31 | 2021-05-11 | Shenyang Fuyang Pharmaceutical Technology Co., Ltd. | Use of carrimycin in Mycobacterium tuberculosis infection resistance |
US11077126B2 (en) | 2017-04-06 | 2021-08-03 | Shenyang Fuyang Pharmaceutical Technology Co., Ltd. | Use of carrimycin and pharmaceutically acceptable salts of carrimycin in manufacturing medicament for treating and/or preventing tumor |
WO2018184587A1 (zh) * | 2017-04-06 | 2018-10-11 | 沈阳福洋医药科技有限公司 | 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用 |
CN110545820B (zh) * | 2017-04-06 | 2023-01-10 | 沈阳福洋医药科技有限公司 | 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用 |
CN110545820A (zh) * | 2017-04-06 | 2019-12-06 | 沈阳福洋医药科技有限公司 | 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用 |
JP2020516609A (ja) * | 2017-04-06 | 2020-06-11 | 沈陽福洋医薬科技有限公司Shenyang Fuyang Pharmaceutical Technology Co., Ltd | 腫瘍を治療および/または予防する薬物の調製におけるカリマイシンおよびその薬学的に許容可能な塩の応用 |
RU2746047C1 (ru) * | 2017-04-06 | 2021-04-06 | Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. | Применение карримицина и его фармацевтически приемлемой соли для производства медикаментов для лечения и/или профилактики опухоли |
CN110384802A (zh) * | 2018-04-17 | 2019-10-29 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗发热的药物、组合产品及其应用 |
CN110384802B (zh) * | 2018-04-17 | 2021-09-17 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗发热的药物、组合产品及其应用 |
CN110384710B (zh) * | 2018-04-17 | 2023-01-10 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗疼痛的药物、组合产品及其应用 |
CN110384710A (zh) * | 2018-04-17 | 2019-10-29 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗疼痛的药物、组合产品及其应用 |
WO2021219112A1 (zh) * | 2020-04-30 | 2021-11-04 | 沈阳福洋医药科技有限公司 | 异戊酰螺旋霉素类化合物或其组合物在制备治疗脓毒症疾病药物中的应用 |
WO2021219113A1 (zh) * | 2020-04-30 | 2021-11-04 | 沈阳福洋医药科技有限公司 | 异戊酰螺旋霉素类化合物或其组合物在制备治疗免疫失调的药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
ES2785644T3 (es) | 2020-10-07 |
EP3384915B1 (en) | 2020-02-19 |
ZA201804398B (en) | 2019-09-25 |
BR112018013327A2 (zh) | 2018-12-04 |
CL2018001804A1 (es) | 2018-09-28 |
AU2016382584A1 (en) | 2018-07-26 |
JP6770584B2 (ja) | 2020-10-14 |
KR20180098624A (ko) | 2018-09-04 |
DK3384915T3 (en) | 2020-05-04 |
JP2019501220A (ja) | 2019-01-17 |
CN105497053B (zh) | 2018-02-13 |
RU2018125622A3 (zh) | 2020-03-26 |
MY191800A (en) | 2022-07-15 |
RU2018125622A (ru) | 2020-01-31 |
PE20190210A1 (es) | 2019-02-07 |
AU2016382584B2 (en) | 2022-01-06 |
PL3384915T3 (pl) | 2020-09-07 |
WO2017114095A1 (zh) | 2017-07-06 |
PH12018501394A1 (en) | 2019-02-27 |
US20190001160A1 (en) | 2019-01-03 |
CA3010020A1 (en) | 2017-07-06 |
UA121159C2 (uk) | 2020-04-10 |
EP3384915A4 (en) | 2018-12-19 |
EP3384915A1 (en) | 2018-10-10 |
US11000708B2 (en) | 2021-05-11 |
RU2733382C2 (ru) | 2020-10-01 |
CO2018007133A2 (es) | 2018-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105497053A (zh) | 可利霉素在抗结核分枝杆菌感染中的应用 | |
Mahajan | Rickettsial diseases | |
CN106188212A (zh) | 闭花木酮衍生物及药学上可接受的盐在抗菌药物中的应用 | |
Adao et al. | Recent advances in Blastocystis sp. research | |
CN109082445A (zh) | 一株银杏内生真菌的代谢产物产品及其在抗菌中的应用 | |
CN112516176B (zh) | 一种杨树型蜂胶乙醇提取物在制备抗菌药物中的应用 | |
Vignesh et al. | Iodine-glycerol as an alternative to lactophenol cotton blue for identification of fungal elements in clinical laboratory | |
Nalamada et al. | Acute postoperative endophthalmitis by Gemella haemolysans | |
CN102861087B (zh) | Houttuynoid D在抗人体真菌药物中的应用 | |
Abbas et al. | Isolation and Screening of Actinomycetes producing Antibacterial compounds from different river sediments | |
CN102861083B (zh) | Houttuynoid B在抗人体真菌药物中的应用 | |
CN105232513A (zh) | 一种组合物及其在抗菌药物中的应用 | |
CN106265635A (zh) | Linderolide H在制备治疗抗结核菌药物中的应用 | |
CN102872145B (zh) | Houttuynoid C在抗人体真菌药物中的应用 | |
CN102872133B (zh) | Houttuynoid E在抗人体真菌药物中的应用 | |
CN106176726A (zh) | Atropurpuran衍生物组合物在抗菌药物中的应用 | |
CN106038555A (zh) | Schiglautone A衍生物的组合物用于制备抗菌药物 | |
Seldina | The Effect of Epigallocatechin gallate (EGCG) on Mycobacterium tuberculosis and Mycobacterium smegmatis | |
CN106074518A (zh) | Artalbic acid衍生物的组合物用于制备抗菌药物 | |
CN105920014A (zh) | Virosaine A的四氢吡咯基和吗啉基衍生物的组合物在抗菌药物中的应用 | |
CN107837259A (zh) | Orientin在制备治疗抗结核菌药物中的应用 | |
CN105998001A (zh) | Salviskinone A的苯并咪唑基和二(2-甲硫基乙基)胺基衍生物的组合物在抗菌药物中的应用 | |
CN106491616A (zh) | Friedolanostanes在制备抗结核菌药物中的应用 | |
CN103479636A (zh) | Lycojaponicumin C在抗人体真菌药物中的应用 | |
CN102895250A (zh) | Houttuynoid A在抗人体真菌药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170804 Address after: Shenbei New Area yaoyang road Shenyang City, Liaoning province 110164 No. 18-12 Applicant after: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: 110042 Liaoning Province, Shenyang City District East Shuncheng Street Yucai Lane No. 18 Applicant before: SHENYANG TONGLIAN GROUP Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200520 Address after: 201612 No.55, Xinfei Road, Songjiang District, Shanghai Patentee after: SHANGHAI TONGLIAN PHARMACEUTICAL Co.,Ltd. Address before: Shenbei New Area yaoyang road Shenyang City, Liaoning province 110164 No. 18-12 Patentee before: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of karimycin in anti-mycobacterium tuberculosis infection Effective date of registration: 20220829 Granted publication date: 20180213 Pledgee: Shengjing bank Yingkou branch of Limited by Share Ltd. Pledgor: SHANGHAI TONGLIAN PHARMACEUTICAL Co.,Ltd. Registration number: Y2022210000135 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |